Side-effects: latest news

Side-effects resources

  • Antiretroviral drugs chart

    A one-page reference guide to the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions....

    From: Antiretroviral drugs chart

    Information level Level 1
  • Managing side-effects that interfere with eating

    Like all medicines, the drugs used to treat HIV can cause side-effects. These are most likely to occur when you first start taking a drug, but...

    From: Booklets

    Information level Level 2
  • Lipodystrophy

    Lipodystrophy is a side-effect of some older anti-HIV drugs which are now rarely used.Lipodystrophy includes both weight gain and weight loss.It is common for people...

    From: Factsheets

    Information level Level 2
  • My drugs chart

    My drugs chart provides information on all the anti-HIV drugs currently licensed for use in Europe.Select your chosen drugs and drag them onto the area...

    From: My drugs chart

  • HIV treatment in women

    The evidence available suggests that HIV treatment works well for women. Unless you are pregnant, the recommendations for HIV treatment are the same for both women and...

    From: Booklets

    Information level Level 2
  • Side-effects

    Like all medications, anti-HIV drugs can cause side-effects and these can be a reason why people don’t take their treatment properly. The risk of side-effects can vary between...

    From: Booklets

    Information level Level 2
  • Side-effects

    Like all medication, anti-HIV drugs can have side-effects. Read more here on what these are and how to deal with them if you experience side-effects....

    From: Living with HIV

    Information level Level 2
  • Side-effects

    The booklet provides information about possible side-effects of HIV treatment. ...

    From: Booklets

    Information level Level 2
  • Side-effects

    Many side-effects are the result of your body getting used to a new drug.Other medicines can be taken to help control side-effects.Possible side-effects should be taken...

    From: Factsheets

    Information level Level 2
  • Neuropathy - nerve pain

    Side-effects Information bookletLactic acidosis Simple factsheet Talking points Online, interactive tool ...

    From: Factsheets

    Information level Level 2
  • Facial wasting

    Facial wasting can be caused by anti-HIV drugs which are no longer recommended.It may be accompanied by other changes in body shapes and blood fats.Facial wasting can...

    From: Factsheets

    Information level Level 2
  • Hyperbilirubinaemia

    High levels of bilirubin in the body can be a side-effect of atazanavir.It can make the skin or eyes more yellow, but is not otherwise harmful.Changing HIV...

    From: Factsheets

    Information level Level 2
  • Lactic acidosis

    Lactic acidosis refers to a build-up of lactic acid in the blood.It is a rare but dangerous side-effect of some anti-HIV drugs.The drugs most likely to cause...

    From: Factsheets

    Information level Level 2
  • Skin problems

    A rash can be a symptom of recent HIV infection.Other infections can also cause skin problems.They may also be a side-effect or allergic reaction to...

    From: Factsheets

    Information level Level 2
  • Pain

    Pain can cause emotional and mental health problems.Medication can be used in both the short and long term to control pain.Treating underlying medical problems may...

    From: Factsheets

    Information level Level 2
  • Nausea and vomiting

    Nausea is a word for the feeling of wanting to vomit or be sick. Most people with HIV will experience nausea and vomiting at some...

    From: Factsheets

    Information level Level 2
  • Diarrhoea

    Diarrhoea is common among people with HIV. It can be a side-effect of anti-HIV drugs as well as some other medicines, such as antibiotics. Diarrhoea...

    From: Factsheets

    Information level Level 2
  • Tiredness and fatigue

    Illnesses and drug side-effects can contribute to fatigue.People often report an increase in their energy levels after starting HIV treatment.A healthy balanced diet may help...

    From: Factsheets

    Information level Level 2
  • Changing treatment due to side-effects

    It’s important to talk to your doctor about your experience of side-effects.If you experience side-effects, there is usually something you can do about them.If side-effects persist, changing...

    From: Factsheets

    Information level Level 2
  • Side effects

    The most common side effects are the result of your body getting used to a new drug. After a few weeks, these side effects usually...

    From: The basics

    Information level Level 1
  • Effect of genetic variation on side-effects of HIV drugs

    In addition to drug levels, the other major area of research interest in pharmacogenetics is the association of human genetic variation with the incidence or...

    From: HIV treatments directory

    Information level Level 4
  • Side-effects

    Information on the side-effects associated with anti-HIV treatments and other drugs, including advice on how to cope with them, and whether treatment should be stopped...

    From: HIV treatments directory

    Information level Level 4

Side-effects features

Side-effects in your own words

Side-effects news from aidsmap

More news

Side-effects news selected from other sources

  • Two Experts Discuss HIV, Abdominal Fat and Body Shape Changes

    Watch TheBody.com's HIV and Aging Expert Nelson Vergel interview Dr. Stephen Grinspoon, Professor at Harvard Medical School and the Director of a Program in Nutritional Metabolism at Massachusetts General Hospital about the causes of body shape changes in HIV -- and most importantly, what you can do about them.

    24 August 2016 | The Body
  • Gilead defeats AIDS activists who claimed the company manipulated patents

    Gilead Sciences won a victory last week when a federal court judge tossed a lawsuit in which an AIDS activist group accused the drug maker of manipulating the patent system in order to thwart competition for its HIV medicines. At issue was tenofovir, or TDF, which Gilead is replacing with a modified version known as TAF.

    13 July 2016 | STAT
  • Fearing Drugs’ Rare Side Effects, Millions Take Their Chances With Osteoporosis

    Millions of Americans are missing out on a chance to avoid debilitating fractures from weakened bones, researchers say, because they are terrified of exceedingly rare side effects from drugs that can help them.

    02 June 2016 | New York Times
  • A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner

    More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. But in 2004 Gilead executives stopped the research, only to restart it as the expiration of tenofovir’s patent in 2018 neared.

    30 May 2016 | Los Angeles Times
  • Gilead announces results from first study to evaluate switching to FTAF-based regimens from Truvada® (FTDF)-based regimens

    Investigational F/TAF-based regimens demonstrate high rates of virologic suppression and improved renal and bone laboratory parameters compared to Truvada-based regimens.

    24 February 2016 | Gilead press release
  • Viread (Tenofovir, TDF) Linked With Liver Disease and Cancer

    Long-term use of Viread (tenofovir disoproxil fumarate, or TDF) is associated with an increased risk of end-stage liver disease (ESLD) as well as hepatocellular carcinoma (HCC, the most common form of liver cancer) among people with HIV.

    14 January 2016 | Poz
  • Short- or Medium-Term PrEP Is Safer Than Aspirin

    Truvada as pre-exposure prophylaxis (PrEP) against HIV has comparable safety to aspirin, at least for the short- and medium-term.

    13 January 2016 | AIDSMeds
  • South African Medicines Agency approves PrEP

    The South African Medicines Control Council (MCC) has approved PrEP. So far it has issued a brief statement, saying that on 28 November it "Approved the use of the fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine to include pre-exposure prophylaxis of HIV(also referred to as PrEP)." The MCC names the separate drugs rather than Truvada, as South Africans take generic versions of the drugs made on licence locally. The MCC does not recommend criteria for PrEP access or name specific populations but instead soliticts applications from organisations that wish to provide PrEP. Its one stipulation is that, since using the drugs for prevention is a new field, records of adverse events in people offered PrEP should be kept by providers.

    08 December 2015 | South African MCC
  • Body fat changes and lactic acidosis with HIV medicines: EMA recommends removal of class warnings for several medicines

    The European Medicines Agency (EMA) has updated the advice on the risk of body fat changes and lactic acidosis with medicines for the treatment of human immunodeficiency virus (HIV) infection. As a result, HIV medicines will no longer require a warning concerning fat redistribution in their product information, and a number of medicines of the class ‘nucleoside and nucleotide analogues’ will no longer require a warning about lactic acidosis.

    26 October 2015 | European Medicines Agency
  • TAF and TDF Compared for Kidney, Bone Toxicity in Black HIV+ Patients

    Including tenofovir alafenamide (TAF) in single-tablet elvitegravir/cobicistat/emtricitabine (E/C/F/TAF) is associated with reduced renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF)-containing single-tablet (E/C/F/TDF) therapy, according to an analysis of data from two Phase 3 trials, reported at IDWeek 2015.

    12 October 2015 | Monthly Prescribing Reference
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close